<DOC>
	<DOCNO>NCT02981316</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety RBX7455 treatment recurrent CDI subject least one recurrence primary episode ( i.e. , least two episode ) complete least two round standard-of-care oral antibiotic therapy .</brief_summary>
	<brief_title>Treatment Recurrent Clostridium Difficile Infection With RBX7455</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Inclusion criterion : 1 . ≥ 18 year old . 2 . Medical record documentation recurrent CDI , define least one recurrence primary episode complete least two round standardofcare oral antibiotic therapy . Study subject diarrhea resolve , i.e. , would less 3 watery bowel movement time study enrollment 48 hour . 3 . A positive stool test presence C. difficile within 30 day prior enrollment standard C. difficile treatment . 4 . Willing able swallow capsule . 5 . Agrees abstain nondietary probiotic duration study . 6 . Agrees abstain vancomycin , metronidazole , fidaxomicin , rifaximin , nitazoxanide IVIG duration study unless prescribe treat recurrent CDI . 7 . Agrees stop proton pump inhibitor H2 blocker medication . 8 . Agrees practice form effective contraception study participation . 9 . Has negative urine pregnancy test time enrollment ( female childbearing potential ) . 10 . Willing able provide inform consent HIPAA authorization . 11 . Willing able complete require Subject Diary . 12 . Willing able meet study requirement , include attend assessment visit phone call . Exclusion criterion : 1 . A known history continue CDI diarrhea , despite course antibiotic prescribe CDI treatment . 2 . Requires continuous antibiotic therapy condition CDI . 3 . Previous fecal transplant . 4 . Previous treatment RBX2660 . 5 . Diagnosis inflammatory bowel disease ( IBD ) , e.g. , ulcerative colitis , Crohn 's disease , microscopic colitis . 6 . Diagnosis irritable bowel syndrome ( IBS ) determine Rome III criterion . 7 . History chronic diarrhea . 8 . History celiac disease . 9 . Disease symptom cause confirmed intestinal pathogen C. difficile . 10 . Unable stop proton pump inhibitor H2 blocker medication . 11 . Colostomy . 12 . Intraabdominal surgery within last 60 day . 13 . Evidence active , severe colitis . 14 . History short gut syndrome . 15 . Requires regular use medication manage bowel hypermotility . 16 . Planned therapy next 3 month may cause diarrhea ( e.g. , chemotherapy ) . 17 . Planned surgery require perioperative antibiotic within 3 month study enrollment . 18 . Life expectancy &lt; 6 month . 19 . Compromised immune system ( e.g. , HIV infection ; AIDSdefining diagnosis CD4 &lt; 200/mm3 ; inherited/primary immune disorder ; immunodeficient immunosuppressed due medical condition medication ; current recent ( &lt; 90 day ) treatment chemotherapy ; current recent ( &lt; 90 day ) treatment immunosuppressant medication . 20 . Taking systemic steroid ( ≥ 20 mg day prednisoneequivalent ) expect steroids enrollment 8 week complete assign study treatment . 21 . An absolute neutrophil count &lt; 1000 cells/µL . 22 . Known suspected current ( &lt; 90 day ) illicit drug use . Note : marijuana use allow . 23 . Pregnant , breastfeeding , intend become pregnant study participation . 24 . Participating clinical trial another investigational product ( drug , device ) complete required followup period . 25 . Subject , opinion investigator , whatever reason , exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>